{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:46:23Z","timestamp":1777391183958,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU2GGH001130"],"award-info":[{"award-number":["NU2GGH001130"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Haiti initiated the scale-up of HIV viral load (VL) testing in 2015\u20132016, with plans to achieve 100% coverage for all patients on antiretroviral therapy (ART) for treatment of HIV\/AIDS. In the absence of HIV drug susceptibility testing, VL testing is a key tool for monitoring response to ART and optimizing treatment results. This study describes trends in expanded use of VL testing, VL results, and use of second-line ART regimens, and explores the association between VL testing and second-line regimen switching in Haiti from 2010 to 2017.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective cohort study with 66,042 patients drawn from 88 of Haiti\u2019s 160 national ART clinics. Longitudinal data from the iSant\u00e9 electronic data system was used to analyze the trends of interest. We described patients\u2019 VL testing status in five categories based on up to two most recent VL test results: no test; suppressed; unsuppressed followed by no test; re-suppressed; and confirmed failure. Among those with confirmed failure, we described ART adherence level. Finally, we used Cox proportional hazards regression to estimate the risk of second-line regimen switching by VL testing status, after adjusting for other individual characteristics.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The number of patients who had tests done increased annually from 11 in 2010 to 18,828 in the first 9 months of 2017, while the number of second-line regimen switches rose from 21 to 279 during this same period. Compared with patients with no VL test, the hazard ratio (HR) for switching to a second-line regimen was 22.2 for patients with confirmed VL failure (95% confidence interval [CI] for HR: 18.8\u201326.3; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005) after adjustment for individual characteristics. Among patients with confirmed VL failure, 44.7% had strong adherence, and fewer than 20% of patients switched to a second-line regimen within 365\u2009days of VL failure.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Haiti has significantly expanded access to VL testing since 2016. In order to promote optimal patient health outcomes, it is essential for Haiti to continue broadening access to confirmatory VL testing, to expand evidence-based initiatives to promote strong ART adherence, and to embrace timely switching for patients with confirmed ART failure despite strong ART adherence.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-04978-9","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T04:15:39Z","timestamp":1587010539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010\u20132017"],"prefix":"10.1186","volume":"20","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesner","family":"Francois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermane","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Kalou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Baptiste","family":"Koama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisma","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Gabriel","family":"Balan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Guy","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Puttkammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"4978_CR1","unstructured":"World Health Organization (WHO). Summary of new recommendations. Geneva: World Health Organization; 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/intro\/rag\/en\/. Accessed 23 Mar 2020."},{"issue":"4","key":"4978_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/QAD.0b013e3282f470be","volume":"22","author":"W Hladik","year":"2008","unstructured":"Hladik W, et al. The estimated burden of HIV\/AIDS in Uganda, 2005\u20132010. Aids. 2008;22(4):503\u201310.","journal-title":"Aids"},{"key":"4978_CR3","unstructured":"World Health Organization (WHO). HIV\/AIDS Data and statistics: World Health Organization, Geneva, Switzerland. 2015. http:\/\/www.who.int\/hiv\/data\/en\/. Accessed 8 Apr 2015."},{"key":"4978_CR4","unstructured":"UNAIDS. Fast-track - ending the AIDS epidemic by 2030. Geneva: UNAIDS; 2015. http:\/\/www.unaids.org\/en\/resources\/documents\/2014\/JC2686_WAD2014report. Accessed 23 Mar 2020."},{"issue":"1","key":"4978_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1473-3099(09)70321-4","volume":"10","author":"AD Harries","year":"2010","unstructured":"Harries AD, et al. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis. 2010;10(1):60\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4978_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/QAI.0b013e3182557785","volume":"60","author":"MP Fox","year":"2012","unstructured":"Fox MP, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (1999). 2012;60(4):428.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"2","key":"4978_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-3156.2009.02445.x","volume":"15","author":"O Keiser","year":"2010","unstructured":"Keiser O, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Tropical Med Int Health. 2010;15(2):251\u20138.","journal-title":"Tropical Med Int Health"},{"issue":"1","key":"4978_CR8","first-page":"63","volume":"20","author":"Z Ataro","year":"2019","unstructured":"Ataro Z. Et al. \"magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis.\" BMC. Pharmacol Toxicol. 2019;20(1):63.","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"4978_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/cid\/cis433","volume":"55","author":"BP Westley","year":"2012","unstructured":"Westley BP, et al. Prediction of treatment failure using 2010 World Health Organization guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis. 2012;55(3):432\u201340.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"4978_CR10","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/QAD.0b013e32830e4cd8","volume":"22","author":"P Mee","year":"2008","unstructured":"Mee P, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. Aids. 2008;22(15):1971\u20137.","journal-title":"Aids"},{"issue":"7","key":"4978_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158881","volume":"11","author":"A Waruru","year":"2016","unstructured":"Waruru A. Et al. \"positive predictive value of the WHO clinical and immunologic criteria to predict viral load failure among adults on first, or second-line antiretroviral therapy in Kenya.\". PLoS One. 2016;11(7):e0158881.","journal-title":"PLoS One"},{"issue":"8","key":"4978_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1365-3156.2009.02309.x","volume":"14","author":"V Oosterhout","year":"2009","unstructured":"Oosterhout V, Joep JG, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Tropical Med Int Health. 2009;14(8):856\u201361.","journal-title":"Tropical Med Int Health"},{"key":"4978_CR13","volume-title":"Guidelines for prevention and treatment opportunistic infections in HIV-infected adults and adolescents; recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America","author":"CA Benson","year":"2009","unstructured":"Benson, Constance A., et al. \"Guidelines for prevention and treatment opportunistic infections in HIV-infected adults and adolescents; recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America.\" (2009)."},{"key":"4978_CR14","unstructured":"World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: World Health Organization; 2016. Accessed 23 Mar 2020."},{"key":"4978_CR15","unstructured":"World Health Organization. World Health Report, Chapter 1: A global emergency: a combined response. Geneva: World Health Organization; 2004. http:\/\/www.who.int\/whr\/2004\/en\/03_chap1_en.pdf. Accessed 23 Mar 2020."},{"key":"4978_CR16","unstructured":"Institute for Health Metrics and Evaluation (IHME). Millennium Development Goals (MDGs) Visualization, Viz Hub. Seattle: IHME; 2013. https:\/\/vizhub.healthdata.org\/mdg\/. Accessed 23 Mar 2020."},{"key":"4978_CR17","unstructured":"UNAIDS. United Nations Program on HIV\/AIDS (UNAIDS), Country Overview in Haiti. http:\/\/www.unaids.org\/en\/regionscountries\/countries\/haiti."},{"key":"4978_CR18","unstructured":"The World Bank. Prevalence of HIV in Haiti. https:\/\/data.worldbank.org\/indicator\/SH.DYN.AIDS.ZS?end=2016&locations=HT&start=1990&view=chart. Accessed 23 Mar 2020."},{"key":"4978_CR19","unstructured":"Monitoring Evaluation et Surveillance Int\u00e9gr\u00e9e (MESI). Patients on Arv Treatment in Progress in Haiti. http:\/\/mesi.ht\/presentation\/modules\/reports.aspx?ID=35. Accessed 23 Mar 2020."},{"key":"4978_CR20","unstructured":"US Department of State. Haiti Country Operational Plan (COP\/ROP) 2016 Strategic Direction Summary. Washington: Office of Global AIDS Coordinator (OGAC), Presidents Emergency Plan for AIDS Relief (PEPFAR); 2016."},{"issue":"2","key":"4978_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/heapol\/czx171","volume":"33","author":"E deRiel","year":"2017","unstructured":"deRiel E, et al. Success factors for implementing and sustaining a mature electronic medical record in a low-resource setting: a case study of iSant\u00e9 in Haiti. Health Policy Plan. 2017;33(2):237\u201346.","journal-title":"Health Policy Plan"},{"issue":"4","key":"4978_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijmedinf.2012.01.011","volume":"81","author":"AI Matheson","year":"2012","unstructured":"Matheson AI, et al. Implementation and expansion of an electronic medical record for HIV care and treatment in Haiti: an assessment of system use and the impact of large-scale disruptions. Int J Med Inform. 2012;81(4):244\u201356.","journal-title":"Int J Med Inform"},{"key":"4978_CR23","volume-title":"Bulletin de Surveillance Epidemiologique VIH\/SIDA","author":"PNLS","year":"2017","unstructured":"PNLS. Bulletin de Surveillance Epidemiologique VIH\/SIDA. Port au Prince: Programme National de Lutte contre le VIH\/SIDA (PNLS), Ministere de Sante Publique et de la Population; 2017."},{"issue":"1","key":"4978_CR24","doi-asserted-by":"publisher","first-page":"e0192077","DOI":"10.1371\/journal.pone.0192077","volume":"13","author":"FJ Louis","year":"2018","unstructured":"Louis FJ, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.","journal-title":"PLoS One"},{"issue":"7","key":"4978_CR25","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","volume":"2","author":"AD Haas","year":"2015","unstructured":"Haas AD, et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. The lancet HIV. 2015;2(7):e271\u20138.","journal-title":"The lancet HIV"},{"key":"4978_CR26","volume-title":"Directives unifi\u00e9es pour la Prise en Charge Clinique, Th\u00e9rapeutique et Prophylactique des personnes \u00e0 risque et infect\u00e9es par le VIH en Haiti","author":"Haiti Ministry of Health and Population (MSPP)","year":"2017","unstructured":"Haiti Ministry of Health and Population (MSPP). Directives unifi\u00e9es pour la Prise en Charge Clinique, Th\u00e9rapeutique et Prophylactique des personnes \u00e0 risque et infect\u00e9es par le VIH en Haiti (2017)."},{"key":"4978_CR27","volume-title":"Manuel des Normes de Prise en Charge Clinique et Th\u00e9rapeutique des Adultes et Adolescents Vivant avec le VIH\/SIDA","author":"Haiti Ministry of Health and Population (MSPP)","year":"2013","unstructured":"Haiti Ministry of Health and Population (MSPP). Manuel des Normes de Prise en Charge Clinique et Th\u00e9rapeutique des Adultes et Adolescents Vivant avec le VIH\/SIDA (2013)."},{"key":"4978_CR28","volume-title":"Manuel des Normes de Prise en Charge Clinique et Th\u00e9rapeutique des Adultes et Adolescents Vivant avec le VIH","author":"Haiti Ministry of Health and Population (MSPP)","year":"2008","unstructured":"Haiti Ministry of Health and Population (MSPP). Manuel des Normes de Prise en Charge Clinique et Th\u00e9rapeutique des Adultes et Adolescents Vivant avec le VIH (2008)."},{"issue":"1","key":"4978_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1472-6963-10-42","volume":"10","author":"D Ross-Degnan","year":"2010","unstructured":"Ross-Degnan D, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10(1):42.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"4978_CR30","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10461-013-0436-x","volume":"17","author":"JH McMahon","year":"2013","unstructured":"McMahon JH, et al. Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS Behav. 2013;17(6):2253\u20139.","journal-title":"AIDS Behav"},{"issue":"7\u20138","key":"4978_CR31","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7\u20138):1280\u20138.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"4978_CR32","doi-asserted-by":"publisher","first-page":"e49091","DOI":"10.1371\/journal.pone.0049091","volume":"7","author":"M Bastard","year":"2012","unstructured":"Bastard M, et al. Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients. PLoS One. 2012;7(11):e49091.","journal-title":"PLoS One"},{"issue":"2","key":"4978_CR33","doi-asserted-by":"publisher","first-page":"e56307","DOI":"10.1371\/journal.pone.0056307","volume":"8","author":"SY Hong","year":"2013","unstructured":"Hong SY, et al. Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One. 2013;8(2):e56307.","journal-title":"PLoS One"},{"issue":"11","key":"4978_CR34","doi-asserted-by":"publisher","first-page":"e112261","DOI":"10.1371\/journal.pone.0112261","volume":"9","author":"N Puttkammer","year":"2014","unstructured":"Puttkammer N, et al. Development of an electronic medical record based alert for risk of HIV treatment failure in a low-resource setting. PLoS One. 2014;9(11):e112261.","journal-title":"PLoS One"},{"issue":"2","key":"4978_CR35","doi-asserted-by":"publisher","first-page":"17375","DOI":"10.7448\/IAS.15.2.17375","volume":"15","author":"M Charles","year":"2012","unstructured":"Charles M, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012;15(2):17375.","journal-title":"J Int AIDS Soc"},{"issue":"14","key":"4978_CR36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/QAD.0b013e328349822f","volume":"25","author":"O Keiser","year":"2011","unstructured":"Keiser O, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS (London, England). 2011;25(14):1761.","journal-title":"AIDS (London, England)"},{"key":"4978_CR37","volume-title":"Ermane Robin Programme National de Lutte contre le VIH\/SIDA, Minist\u00e8re de la Sant\u00e9 Publique et de la Population, personal communication","author":"K Fran\u00e7ois","year":"2018","unstructured":"Fran\u00e7ois K. Ermane Robin Programme National de Lutte contre le VIH\/SIDA, Minist\u00e8re de la Sant\u00e9 Publique et de la Population, personal communication; 2018."},{"issue":"1","key":"4978_CR38","doi-asserted-by":"publisher","first-page":"1330915","DOI":"10.1080\/16549716.2017.1330915","volume":"10","author":"JW Domercant","year":"2017","unstructured":"Domercant JW, et al. Attrition from antiretroviral treatment services among pregnant and non-pregnant patients following adoption of Option B+ in Haiti. Glob Health Action. 2017;10(1):1330915.","journal-title":"Glob Health Action"},{"key":"4978_CR39","volume-title":"\u201cRoll-out and outcomes of the \u2018test and start\u2019 approach within Haiti\u2019s national ART program\u201d, bulletin Epidemiologique du PNLS, Haiti Ministry of Health and Population","author":"N Puttkammer","year":"2018","unstructured":"Puttkammer, Nancy, et al. \u201cRoll-out and outcomes of the \u2018test and start\u2019 approach within Haiti\u2019s national ART program\u201d, bulletin Epidemiologique du PNLS, Haiti Ministry of Health and Population, 2018."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-04978-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:48:39Z","timestamp":1618534119000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-04978-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4978"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-04978-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol for this study was reviewed and approved by Haiti\u2019s Comit\u00e9 National de Bio\u00e9thique and the University of Washington\u2019s Human Subjects Division. The protocol was also reviewed in accordance with the US Centers for Disease Control and Prevention (CDC) human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}